PODS™ Human LIF

Code Description Price Qty
PPH200-50 PODS™ Human LIF, 50 million £95.00
PPH200-250 PODS™ Human LIF, 250 million £295.00
PPH200-1000 PODS™ Human LIF, 1 billion £995.00

PODS™ Technology

PODS™ proteins are made using an insect cell expression system in which the active protein is co-expressed alongside polyhedrin carrier protein. Polyhedrin forms microcrystals within insect cells which specifically capture the active protein to form a co-crystal complex. The active protein is captured in its nascent, natively folded form with limited scope for proteolytic degradation. Consequently, excellent levels of bioactivity are observed. The PODS™ crystals provide a sustained release mechanism and can be used to functionalize surfaces. For further details, please refer to the PODS™ Technology page.

Product Description

The product contains the polyhedrin protein co-crystalized with Human LIF. Leukemia Inhibitory Factor (LIF) is a member of the interleukin-6 (IL-6) family that is made by a variety of adult and embryonic tissues. LIF signals through the glycoprotein 130 (gp130)/LIF receptor (LIFR) heterodimer to activate STAT3 and MAPK signaling. LIF functions during hematopoietic differentiation, neuronal cell differentiation, kidney development, and inflammatory processes. Human LIF may also be an important factor during human embryonic stem cell (hESC) self-renewal, pluripotency, and embryonic implantation.

Usage Recommendation

PODS™ crystals provide a depot of proteins which are steadily secreted. It has been estimated that the biological activity of 50 million PODS™ crystals generates the same peak dose as 3.3 μg of standard recombinant protein. However, at 5 days following the start of seeding the PODS™ crystals, there are more than 50% of these peak levels still present in the culture system. Ultimately, the amount of PODS™ crystals that is optimal for a particular experiment should be determined empirically. Based on previous data, we suggest using 50 million PODS™ crystals in place of 3.3 μg of standard growth factor as a starting point."

To control for cross-reactivity with cells or as a negative control, we recommend using PODS™ growth factors alongside PODS™ Empty crystals, as the latter do not contain or release cargo protein.

AA Sequence

MADVAGTSNR DFRGREQRLF NSEQYNYNNS KNSRPSTSLY KKAGLSPLPI TPVNATCAIR HPCHNNLMNQ IRSQLAQLNG SANALFILYY TAQGEPFPNN LDKLCGPNVT DFPPFHANGT EKAKLVELYR IVVYLGTSLG NITRDQKILN PSALSLHSKL NATADILRGL LSNVLCRLCS KYHVGHVDVT YGPDTSGKDV FQKKKLGCQL LGKYKQIIAV LAQAF

Alternative Names

Leukocyte Inhibitory Factor, leukemia inhibitory factor, cholinergic differentiation factor
Product Details
Length 225 aa
Molecular Weight 25 kDa
Structure Monomer
Source Spodoptera frugiperda (Sf9) cell culture
Accession Number P15018
Endotoxin Level <0.06 EU/ml as measured by gel clot LAL assay
Formulation PODS™ were lyophilized from a volatile solution
Reconstitution

PODS™ protein crystals may be reconstituted at 200 million PODS™/ml in water. 20% glucose has a buoyant density closer to PODS™ protein crystals and can be useful for aliquoting.

PODS™ protein crystals are highly stable when stored in aqueous solution (pH range 6 - 8).

Stability and Storage Upon receipt, store at 4°C. PODS™ protein crystals are stable for at least 1 year when dry and 6 months when resuspended.

References

Fasséli Coulibaly, Elaine Chiu, Keiko Ikeda, Sascha Gutmann, Peter W. Haebel, Clemens Schulze-Briese, Hajime Mori, and Peter Metcalf. The molecular organization of cypovirus polyhedra. (2007) Nature. 446: 97-101.

Rey FA. Virology: Holed up in a natural crystal. (2007) Nature. 446: 35-37.

Mori H. Immobilization of Bioactive Growth Factors into Cubic Proteinous Microcrystals (Cypovirus Polyhedra) and Control of Cell Proliferation and Differentiation. (2010) NSTI-Nanotech. 3: 222-225.

Nishishita N, Ijiri H, Takenaka C, Kobayashi K, Goto K, Kotani E, Itoh T, Mori H, Kawamata S. The use of leukemia inhibitory factor immobilized on virus-derived polyhedra to support the proliferation of mouse embryonic and induced pluripotent stem cells. (2011) Biomaterials. 32(14): 3555-3563.

Takatsune Shimizu, Tomoki Ishikawa, Sayaka Iwai, Arisa Ueki, Eiji Sugihara, Nobuyuki Onishi, Shinji Kuninaka, Takeshi Miyamoto, Yoshiaki Toyama, Hiroshi Ijiri, et al. Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma. (2012) Molecular Cancer Research. 10: 454-468.

Satoshi Abe, Hiroshi Ijiri, Hashiru Negishi, Hiroyuki Yamanaka, Katsuhito Sasaki, Kunio Hirata, Hajime Mori, and Takafumi Ueno. Design of Enzyme-Encapsulated Protein Containers by In-Vivo Crystal Engineering. (2015) Advanced Materials. 27(48): 7951-7956.